Patents by Inventor Charles Q. Huang
Charles Q. Huang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8504620Abstract: A system, method and medium of sending messages in a distributed data processing network is described, and contemplates receiving a message that includes subject information that is generated based on one or more pre-selected portions as the message is generated. A message delivery system in a client-server environment is also described. The message delivery system includes a server configured to receive a message that includes subject information that is generated based on one or more pre-selected portions as the message is created and configured to forward the message based on the subject information.Type: GrantFiled: January 11, 2007Date of Patent: August 6, 2013Assignee: Applied Materials, Inc.Inventors: Yueh-Shian Chi, Parris C M Hawkins, Charles Q. Huang
-
Patent number: 7915420Abstract: The invention provides novel GlyT2 inhibiting compounds useful in modulating, treating, or preventing: anxiolytic disorders; a condition requiring treatment of injured mammalian nerve tissue; a condition amenable to treatment through administration of a neurotrophic factor; a neurological disorder; or obesity; an obesity-related disorder.Type: GrantFiled: July 19, 2007Date of Patent: March 29, 2011Assignee: Janssen Pharmaceutica NVInventors: Charles Q. Huang, Timothy W. Lovenberg, Alejandro Santillán, Jr., Liu Y. Tang, Ronald L. Wolin
-
Patent number: 7419983Abstract: GnRH receptor antagonists are disclosed that have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure: wherein R1a, R1b, R1c, R2a, R2b, R3, R4, R5, R6 and X are as defined herein, including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.Type: GrantFiled: January 25, 2007Date of Patent: September 2, 2008Assignee: Neurocrine Biosciences, Inc.Inventors: Zhiqiang Guo, Yongsheng Chen, Dongpei Wu, Chen Chen, Warren Wade, Wesley J. Dwight, Charles Q. Huang, Fabio C. Tucci
-
Patent number: 7329669Abstract: GnRH receptor antagonists are disclosed that have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure: wherein R1a, R1b, R2a, R2b, R3, R4, R5, R6, R7 and X are as defined herein, including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.Type: GrantFiled: June 2, 2006Date of Patent: February 12, 2008Assignee: Neurocrine Biosciences, Inc.Inventors: Yun-Fei Zhu, Collin Regan, Jaimie K Rueter, Zhiqiang Guo, Yongsheng Chen, Charles Q Huang
-
Patent number: 7276610Abstract: The invention provides novel GlyT2 inhibiting compounds useful in modulating, treating, or preventing: anxiolytic disorders; a condition requiring treatment of injured mammalian nerve tissue; a condition amenable to treatment through administration of a neurotrophic factor; a neurological disorder; or obesity; an obesity-related disorder.Type: GrantFiled: August 17, 2004Date of Patent: October 2, 2007Assignee: Janssen Pharaceutica, NVInventors: Charles Q. Huang, Timothy W. Lovenberg, Alejandro Santillán, Jr., Liu Y. Tang, Ronald L. Wolin
-
Patent number: 7229995Abstract: GnRH receptor antagonists are disclosed that have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure: wherein n, R1a, R1b, R1c, R2a, R2b, R3, R4, R5, R6 and X are as defined herein, including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.Type: GrantFiled: November 1, 2005Date of Patent: June 12, 2007Assignee: Neurocrine Biosciences, Inc.Inventors: Charles Q. Huang, Chen Chen, Yongsheng Chen, Zhiqiang Guo, Warren Wade, Martin Rowbottom, Jaimie K. Rueter
-
Patent number: 7188142Abstract: A system, method and medium of sending messages in a distributed data processing network is described, and contemplates receiving a message that includes subject information that is generated based on one or more pre-selected portions as the message is generated. A message delivery system in a client-server environment is also described. The message delivery system includes a server configured to receive a message that includes subject information that is generated based on one or more pre-selected portions as the message is created and configured to forward the message based on the subject information.Type: GrantFiled: November 30, 2000Date of Patent: March 6, 2007Assignee: Applied Materials, Inc.Inventors: Yueh-shian T. Chi, Parris C. M. Hawkins, Charles Q. Huang
-
Patent number: 7176211Abstract: GnRH receptor antagonists are disclosed that have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure: wherein R1a, R1b, R1c, R2a, R2b, R3, R4, R5, R6 and X are as defined herein, including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.Type: GrantFiled: October 14, 2005Date of Patent: February 13, 2007Assignee: Neurocrine Biosciences, Inc.Inventors: Zhiqiang Guo, Yongsheng Chen, Dongpei Wu, Chen Chen, Warren Wade, Wesley J. Dwight, Charles Q. Huang, Fabio C. Tucci
-
Patent number: 7074797Abstract: This invention concerns compounds of formula including the stereoisomers and the pharmaceutically acceptable acid addition salt forms thereof, wherein R1 is NR4R5 or OR5; R2 is C1-6alkyl, C1-6alkyloxy or C1-6alkylthio; R3 is hydrogen, C1-6alkyl, C1-6alkylsulfonyl, C1-6alkylsulfoxy or C1-6alkylthio; R4 is hydrogen, C1-6alkyl, mono- or di(C3-6cycloalkyl)methyl, C3-6cycloalkyl, C3-6alkenyl, hydroxyC1-6alkyl, C1-6alkylcarbonyloxyC1-6alkyl or C1-6alkyloxyC1-6alkyl; R5 is C1-8alkyl, mono- or di(C3-6cycloalkyl)methyl, A1CH2, C1-6alkyloxyC1-6alkyl, hydroxyC1-6alkyl, C3-6alkenyl, thienylmethyl, furanylmethyl, C1-6alkylthioC1-6alkyl, morpholinyl, mono- or di(C1-6alkyl)aminoC1-6alkyl, di(C1-6alkyl)amino, C1-6alkylcarbonylC1-6alkyl, C1-6alkyl substituted with imidazolyl; or a radical of formula —Alk—O—CO—Ar1; or R4 and R5 taken together with the nitrogen atom to which they are attached may form an optionally substituted pyrrolidinyl, piperidinyl, homopiperidinyl or morpholinyl group; having CRF receptor antagonisticType: GrantFiled: September 19, 2003Date of Patent: July 11, 2006Assignee: Neurocrine Biosciences, Inc.Inventors: Chen Chen, Thomas R Webb, James R McCarthy, Terence Moran, Keith M Wilcoxen, Charles Q Huang
-
Patent number: 7071200Abstract: GnRH receptor antagonists are disclosed that have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure: wherein R1a, R1b, R2a, R2b, R3, R4, R5, R6, R7 and X are as defined herein, including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.Type: GrantFiled: July 6, 2004Date of Patent: July 4, 2006Assignee: Neurocrine Biosciences, Inc.Inventors: Yun-Fei Zhu, Collin Regan, Jaimie K. Rueter, Zhiqiang Guo, Yongsheng Chen, Charles Q. Huang
-
Patent number: 7056927Abstract: GnRH receptor antagonists are disclosed that have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure: wherein R1a, R1b, R1c, R2a, R2b, R3, R4, R5, R6 and X are as defined herein, including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.Type: GrantFiled: July 6, 2004Date of Patent: June 6, 2006Assignee: Neurocrine Biosciences, Inc.Inventors: Zhiqiang Guo, Yongsheng Chen, Dongpei Wu, Chen Chen, Warren Wade, Wesley J. Dwight, Charles Q. Huang, Fabio C. Tucci
-
Patent number: 7015226Abstract: GnRH receptor antagonists are disclosed that have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure: wherein n, R1a, R1b, R1c, R2a, R2b, R3, R4, R5, R6 and X are as defined herein, including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.Type: GrantFiled: July 6, 2004Date of Patent: March 21, 2006Assignee: Neurocrine Biosciences, Inc.Inventors: Charles Q. Huang, Chen Chen, Yongsheng Chen, Zhiqiang Guo, Warren Wade, Martin Rowbottom, Jaimie K. Rueter
-
Publication number: 20040266799Abstract: CRF receptor antagonists are disclosed which have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in a warm-blooded animals, such as stroke.Type: ApplicationFiled: April 22, 2004Publication date: December 30, 2004Applicant: Neurocrine Biosciences, Inc.Inventors: Mustapha Haddach, Marion C. Lanier, Charles Q. Huang, James R. McCarthy
-
Publication number: 20040157851Abstract: CRF receptor antagonists are disclosed which have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in a warm-blooded animals, such as stroke.Type: ApplicationFiled: November 4, 2003Publication date: August 12, 2004Applicant: Neurocrine Biosciences, Inc.Inventors: Mustapha Haddach, Brian P. Dyck, Charles Q. Huang, Jodie Nelson, Zhiqiang Guo, James R. McCarthy
-
Publication number: 20040127483Abstract: This invention concerns compounds of formula 1Type: ApplicationFiled: September 19, 2003Publication date: July 1, 2004Applicant: Neurocrine Biosciences, Inc.Inventors: Chen Chen, Thomas R. Webb, James R. McCarthy, Terence J. Moran, Keith M. Wilcoxen, Charles Q. Huang
-
Publication number: 20040121999Abstract: This invention concerns compounds of formula 1Type: ApplicationFiled: August 28, 2003Publication date: June 24, 2004Applicant: Neurocrine Biosciences, Inc.Inventors: Chen Chen, Keith M. Wilcoxen, Charles Q. Huang, Mustapha Hadduch, James R. McCarthy
-
Patent number: 6747034Abstract: CRF receptor antagonists are disclosed which have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in a warm-blooded animals, such as stroke.Type: GrantFiled: November 2, 2001Date of Patent: June 8, 2004Assignee: Neurocrine Biosciences, Inc.Inventors: Mustapha Haddach, Marion C. Lanier, Charles Q. Huang, James R. McCarthy
-
Publication number: 20040087589Abstract: CRF receptor antagonists are disclosed which have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in a warm-blooded animals, such as stroke.Type: ApplicationFiled: January 8, 2003Publication date: May 6, 2004Applicant: Neurocrine Biosciences, Inc.Inventors: Mustapha Haddach, Brian P. Dyck, Charles Q. Huang, Jodie Nelson, Zhiqiang Guo, James R. McCarthy
-
Patent number: 6613777Abstract: This invention concerns compounds of formula including the stereoisomers and the pharmaceutically acceptable acid addition salt forms thereof, wherein R1 is C1-6alkyl, NR5R6, OR6 or SR6; R2 is C1-6alkyl, C1-6alkyloxy, or C1-6alkylthio; R3 is Ar1 or Het1; R4 is hydrogen or C1-6alkyl; R5 is hydrogen, C1-8alkyl, mono- or di(C3-6cycloalkyl)methyl, C3-6cycloalkyl, C3-6alkenyl, hydroxyC1-6alkyl, C1-6alkylcarbonyloxyC1-6alkyl, mono- or di(C1-6alkyl)amino-C1-6alkyl or C1-6alkyloxyC1-6alkyl; R6 is C1-8alkyl, mono- or di(C3-6cycloalkyl)methyl, Ar2C1-6alkyl, Ar2oxyC1-6alkyl, C1-6alkyloxyC1-6alkyl, hydroxyC1-6alkyl, C3-6alkenyl, thienylmethyl, furanylmethyl, tetrahydrofuranylmethyl, C1-6alkylthioC1-6alkyl, mono- or di(C1-6alkyl)aminoC1-6alkyl, di(C1-6alkyl)amino, or C1-6alkylcarbonylC1-6alkyl; or R5 and R6 taken together with the nitrogen atom to which they are attached may form a pyrrolidinyl, piperidinyl, homopiperidinyl, morpholinyl, or thiomorpholinyl group, optionally substituted with 1 or 2 substiType: GrantFiled: February 20, 2001Date of Patent: September 2, 2003Inventors: Chen Chen, Keith M. Wilcoxen, Charles Q. Huang, Mustapha Hadduch, James R. McCarthy
-
Patent number: 6531475Abstract: CRF receptor antagonists are disclosed which have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in a warm-blooded animals, such as stroke. The CRF receptor antagonists of this invention have the following structure: including stereoisomers and pharmaceutically acceptable salts thereof, wherein n, m, A, B, C, R, R1, R2 and Ar are as defined herein.Type: GrantFiled: May 18, 2000Date of Patent: March 11, 2003Assignee: Neurocrine Biosciences, Inc.Inventors: Mustapha Haddach, Brian P. Dyck, Charles Q. Huang, Jodie Nelson, Zhiqiang Guo, James R. McCarthy